{
 "disease": "thyroid-cancer",
 "label": "Thyroid cancer",
 "url": "https://usebiotransfer.org/disease/thyroid-cancer/",
 "built": "2026-09-12",
 "facts_hash": {
  "answers": "b06f196670d2",
  "targets": "aa7ad3ec1b4b"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-12",
  "trials": "2026-09-12"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "BRAF",
   "ensembl": "ENSG00000157764",
   "n_drug_entries": 18,
   "n_distinct_drugs": 16,
   "drugs": {
    "ARQ-736": "PHASE_1",
    "BELVARAFENIB": "PHASE_2",
    "CEP-32496": "PHASE_1_2",
    "DABRAFENIB": "APPROVAL",
    "ENCORAFENIB": "APPROVAL",
    "LIFIRAFENIB": "PHASE_1_2",
    "LY-3009120": "PHASE_1",
    "NAPORAFENIB": "PHASE_3",
    "PLIXORAFENIB": "PHASE_2",
    "RAF-265": "PHASE_2",
    "REGORAFENIB": "APPROVAL",
    "RG-7256": "PHASE_1",
    "SORAFENIB": "APPROVAL",
    "TOVORAFENIB": "APPROVAL",
    "VEMURAFENIB": "APPROVAL",
    "XL-281": "PHASE_1_2"
   },
   "approved": [
    "DABRAFENIB",
    "ENCORAFENIB",
    "REGORAFENIB",
    "SORAFENIB",
    "TOVORAFENIB",
    "VEMURAFENIB"
   ],
   "n_approved": 6,
   "approved_for": {
    "DABRAFENIB": [
     "metastatic melanoma",
     "melanoma",
     "low grade glioma",
     "glioma"
    ],
    "ENCORAFENIB": [
     "melanoma",
     "colorectal neoplasm",
     "metastatic melanoma"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "SORAFENIB": [
     "renal cell carcinoma",
     "hepatocellular carcinoma",
     "thyroid gland carcinoma"
    ],
    "TOVORAFENIB": [
     "glioma",
     "low grade glioma"
    ],
    "VEMURAFENIB": [
     "melanoma",
     "metastatic melanoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "RET",
   "ensembl": "ENSG00000165731",
   "n_drug_entries": 16,
   "n_distinct_drugs": 14,
   "drugs": {
    "ALECTINIB": "APPROVAL",
    "BOS-589": "PHASE_2",
    "CEP-2563": "PHASE_1",
    "CEP-32496": "PHASE_1_2",
    "LESTAURTINIB": "APPROVAL",
    "MOTESANIB": "PHASE_3",
    "PRALSETINIB": "APPROVAL",
    "QUIZARTINIB": "APPROVAL",
    "REGORAFENIB": "APPROVAL",
    "SELPERCATINIB": "APPROVAL",
    "SORAFENIB": "APPROVAL",
    "SUNITINIB": "APPROVAL",
    "SUNITINIB MALATE": "APPROVAL",
    "VANDETANIB": "APPROVAL"
   },
   "approved": [
    "ALECTINIB",
    "LESTAURTINIB",
    "PRALSETINIB",
    "QUIZARTINIB",
    "REGORAFENIB",
    "SELPERCATINIB",
    "SORAFENIB",
    "SUNITINIB",
    "SUNITINIB MALATE",
    "VANDETANIB"
   ],
   "n_approved": 10,
   "approved_for": {
    "ALECTINIB": [
     "non-small cell lung carcinoma"
    ],
    "LESTAURTINIB": [
     "acute myeloid leukemia by FAB classification"
    ],
    "PRALSETINIB": [
     "medullary thyroid gland carcinoma",
     "non-small cell lung carcinoma"
    ],
    "QUIZARTINIB": [
     "acute myeloid leukemia by FAB classification"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "SELPERCATINIB": [
     "medullary thyroid gland carcinoma",
     "non-small cell lung carcinoma",
     "thyroid cancer",
     "thyroid tumor"
    ],
    "SORAFENIB": [
     "renal cell carcinoma",
     "thyroid gland carcinoma",
     "hepatocellular carcinoma"
    ],
    "SUNITINIB": [
     "gastrointestinal stromal tumor",
     "renal cell carcinoma",
     "neuroendocrine neoplasm"
    ],
    "SUNITINIB MALATE": [
     "renal cell carcinoma",
     "gastrointestinal stromal tumor",
     "neuroendocrine neoplasm"
    ],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "NRAS",
   "ensembl": "ENSG00000213281",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "SALIRASIB": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "HRAS",
   "ensembl": "ENSG00000174775",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "SALIRASIB": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "TERT",
   "ensembl": "ENSG00000164362",
   "n_drug_entries": 2,
   "n_distinct_drugs": 1,
   "drugs": {
    "IMETELSTAT": "APPROVAL"
   },
   "approved": [
    "IMETELSTAT"
   ],
   "n_approved": 1,
   "approved_for": {
    "IMETELSTAT": [
     "anemia",
     "myelodysplastic syndrome"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "NTRK1",
   "ensembl": "ENSG00000198400",
   "n_drug_entries": 17,
   "n_distinct_drugs": 16,
   "drugs": {
    "ALTIRATINIB": "PHASE_1",
    "AZD-6918": "PHASE_1",
    "AZD-7451": "PHASE_1",
    "CENEGERMIN": "APPROVAL",
    "CEP-2563": "PHASE_1",
    "ENTRECTINIB": "APPROVAL",
    "GZ-389988": "PHASE_2",
    "LAROTRECTINIB": "APPROVAL",
    "LESTAURTINIB": "APPROVAL",
    "MILCICLIB": "PHASE_2",
    "PEGCANTRATINIB": "PHASE_2",
    "PLX-7486": "PHASE_1",
    "REGORAFENIB": "APPROVAL",
    "REPOTRECTINIB": "APPROVAL",
    "SELITRECTINIB": "PHASE_1",
    "TALETRECTINIB": "PHASE_3"
   },
   "approved": [
    "CENEGERMIN",
    "ENTRECTINIB",
    "LAROTRECTINIB",
    "LESTAURTINIB",
    "REGORAFENIB",
    "REPOTRECTINIB"
   ],
   "n_approved": 6,
   "approved_for": {
    "CENEGERMIN": [
     "keratitis",
     "eye disorder"
    ],
    "ENTRECTINIB": [
     "non-small cell lung carcinoma"
    ],
    "LAROTRECTINIB": [
     "metastasis"
    ],
    "LESTAURTINIB": [
     "acute myeloid leukemia by FAB classification"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "REPOTRECTINIB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "ALK",
   "ensembl": "ENSG00000171094",
   "n_drug_entries": 12,
   "n_distinct_drugs": 11,
   "drugs": {
    "ALECTINIB": "APPROVAL",
    "ASP-3026": "PHASE_1",
    "BRIGATINIB": "APPROVAL",
    "CEP-37440": "PHASE_1",
    "CERITINIB": "APPROVAL",
    "CONTELTINIB": "PHASE_1_2",
    "CRIZOTINIB": "APPROVAL",
    "ENSARTINIB": "PHASE_3",
    "ENTRECTINIB": "APPROVAL",
    "LORLATINIB": "APPROVAL",
    "PLB1003": "PHASE_1"
   },
   "approved": [
    "ALECTINIB",
    "BRIGATINIB",
    "CERITINIB",
    "CRIZOTINIB",
    "ENTRECTINIB",
    "LORLATINIB"
   ],
   "n_approved": 6,
   "approved_for": {
    "ALECTINIB": [
     "non-small cell lung carcinoma"
    ],
    "BRIGATINIB": [
     "non-small cell lung carcinoma",
     "anaplastic large cell lymphoma"
    ],
    "CERITINIB": [
     "non-small cell lung carcinoma"
    ],
    "CRIZOTINIB": [
     "non-small cell lung carcinoma"
    ],
    "ENTRECTINIB": [
     "non-small cell lung carcinoma"
    ],
    "LORLATINIB": [
     "lymphoma",
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Phase 1 Clinical"
    }
   ]
  },
  {
   "symbol": "PIK3CA",
   "ensembl": "ENSG00000121879",
   "n_drug_entries": 32,
   "n_distinct_drugs": 31,
   "drugs": {
    "ALPELISIB": "APPROVAL",
    "APITOLISIB": "PHASE_2",
    "AZD-6482": "UNKNOWN",
    "BAY-1082439": "PHASE_1",
    "BGT-226": "PHASE_1_2",
    "BUPARLISIB": "PHASE_3",
    "COPANLISIB": "APPROVAL",
    "DACTOLISIB": "PHASE_3",
    "DS-7423": "PHASE_1",
    "FIMEPINOSTAT": "PHASE_2",
    "GEDATOLISIB": "PHASE_3",
    "GSK-1059615": "PHASE_1",
    "INAVOLISIB": "APPROVAL",
    "IZORLISIB": "PHASE_1_2",
    "OMIPALISIB": "PHASE_1",
    "PANULISIB": "PHASE_1",
    "PAXALISIB": "PHASE_2_3",
    "PF-04691502": "PHASE_2",
    "PICTILISIB": "PHASE_2",
    "PILARALISIB": "PHASE_2",
    "PKI-179": "PHASE_1",
    "RECILISIB": "PHASE_1",
    "SAMOTOLISIB": "PHASE_2",
    "SERABELISIB": "PHASE_2",
    "SF-1126": "PHASE_2",
    "SONOLISIB": "PHASE_2",
    "TASELISIB": "PHASE_3",
    "VOXTALISIB": "PHASE_2",
    "VS-5584": "PHASE_1",
    "WX-037": "PHASE_1",
    "ZSTK-474": "PHASE_1"
   },
   "approved": [
    "ALPELISIB",
    "COPANLISIB",
    "INAVOLISIB"
   ],
   "n_approved": 3,
   "approved_for": {
    "ALPELISIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "COPANLISIB": [
     "follicular lymphoma",
     "non-Hodgkin lymphoma",
     "neoplasm of mature B-cells"
    ],
    "INAVOLISIB": [
     "breast neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "TSHR",
   "ensembl": "ENSG00000165409",
   "n_drug_entries": 2,
   "n_distinct_drugs": 2,
   "drugs": {
    "THYROTROPIN": "APPROVAL",
    "THYROTROPIN ALFA": "APPROVAL"
   },
   "approved": [
    "THYROTROPIN",
    "THYROTROPIN ALFA"
   ],
   "n_approved": 2,
   "approved_for": {
    "THYROTROPIN": [
     "hypothyroidism"
    ],
    "THYROTROPIN ALFA": [
     "thyroid gland carcinoma",
     "thyroid cancer",
     "thyroid tumor"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "SLC5A5",
   "ensembl": "ENSG00000105641",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    }
   ]
  },
  {
   "symbol": "PAX8",
   "ensembl": "ENSG00000125618",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "RET": {
    "n": 57,
    "n_observational": 16,
    "n_active": 25,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT05451602",
      "title": "HEC169096 in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05668962",
      "title": "Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC",
      "status": "RECRUITING",
      "last_update": "2024-12-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05830500",
      "title": "Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma",
      "status": "RECRUITING",
      "last_update": "2023-07-25",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06195228",
      "title": "A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06458036",
      "title": "Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06475989",
      "title": "Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06482086",
      "title": "Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2024-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06860971",
      "title": "A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07383246",
      "title": "CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC",
      "status": "RECRUITING",
      "last_update": "2026-02-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07704658",
      "title": "Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00098345",
      "title": "Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00215605",
      "title": "Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2013-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00358956",
      "title": "A Study To Assess ZD6474 (ZACTIMA\u2122) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2017-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00410761",
      "title": "An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2025-09-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00514046",
      "title": "Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2020-12-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00537095",
      "title": "Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00704730",
      "title": "Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2021-04-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00923247",
      "title": "A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)",
      "status": "TERMINATED",
      "last_update": "2018-11-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00937417",
      "title": "S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2017-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01100619",
      "title": "A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2013-09-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01298323",
      "title": "Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment",
      "status": "COMPLETED",
      "last_update": "2026-04-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01496313",
      "title": "To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2025-10-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01539655",
      "title": "Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib",
      "status": "COMPLETED",
      "last_update": "2017-05-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01661179",
      "title": "Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-12-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01709435",
      "title": "Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-12-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01811212",
      "title": "Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01831726",
      "title": "Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib",
      "status": "COMPLETED",
      "last_update": "2017-03-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01838642",
      "title": "Ponatinib for Advanced Medullary Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2017-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01876784",
      "title": "Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2024-07-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01896479",
      "title": "A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-02",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02041260",
      "title": "A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting",
      "status": "UNKNOWN",
      "last_update": "2021-10-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02592356",
      "title": "Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer",
      "status": "COMPLETED",
      "last_update": "2024-03-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02867592",
      "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03037385",
      "title": "Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-05-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03131206",
      "title": "A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2021-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03157128",
      "title": "A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03630120",
      "title": "Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2021-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03690388",
      "title": "A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03780517",
      "title": "Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors",
      "status": "COMPLETED",
      "last_update": "2023-10-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03899792",
      "title": "A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03914300",
      "title": "Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04161391",
      "title": "Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations",
      "status": "TERMINATED",
      "last_update": "2024-06-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04211337",
      "title": "A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04280081",
      "title": "A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04400474",
      "title": "Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study",
      "status": "COMPLETED",
      "last_update": "2025-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04514484",
      "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04759911",
      "title": "Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04760288",
      "title": "A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).",
      "status": "WITHDRAWN",
      "last_update": "2024-01-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05241834",
      "title": "A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment",
      "status": "COMPLETED",
      "last_update": "2026-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05265091",
      "title": "A Study of KL590586 in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05278364",
      "title": "Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor",
      "status": "UNKNOWN",
      "last_update": "2023-04-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05660954",
      "title": "Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.",
      "status": "COMPLETED",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05675605",
      "title": "A Study of TY-1091 in Patients With Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07010393",
      "title": "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07252661",
      "title": "Study of ACC-1898 in Adult Participants With Advanced Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07620574",
      "title": "Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "RET",
     "selpercatinib",
     "pralsetinib",
     "vandetanib",
     "cabozantinib"
    ]
   },
   "BRAF V600E": {
    "n": 37,
    "n_observational": 5,
    "n_active": 20,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03975231",
      "title": "Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05503797",
      "title": "A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations",
      "status": "RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05768178",
      "title": "DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.",
      "status": "RECRUITING",
      "last_update": "2025-11-24",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06079333",
      "title": "NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)",
      "status": "RECRUITING",
      "last_update": "2023-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06195228",
      "title": "A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06440850",
      "title": "Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06475989",
      "title": "Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06482086",
      "title": "Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2024-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06902376",
      "title": "XL092 and Cemiplimab in BRAF WT Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07440290",
      "title": "DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01286753",
      "title": "A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation",
      "status": "COMPLETED",
      "last_update": "2016-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01417442",
      "title": "BRAF V600E Mutations In Papillary Thyroid Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2011-08-16",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01534897",
      "title": "Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436",
      "status": "COMPLETED",
      "last_update": "2017-03-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01709292",
      "title": "Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01723202",
      "title": "Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2025-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01947023",
      "title": "Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02034110",
      "title": "Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers",
      "status": "COMPLETED",
      "last_update": "2023-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02145143",
      "title": "Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study",
      "status": "COMPLETED",
      "last_update": "2025-06-18",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02456701",
      "title": "Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379",
      "status": "COMPLETED",
      "last_update": "2017-09-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03176485",
      "title": "Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors",
      "status": "COMPLETED",
      "last_update": "2019-01-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03181100",
      "title": "Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03244956",
      "title": "Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2026-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04238624",
      "title": "Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04418167",
      "title": "JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations",
      "status": "SUSPENDED",
      "last_update": "2025-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04439292",
      "title": "Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04462471",
      "title": "Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers",
      "status": "COMPLETED",
      "last_update": "2025-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04544111",
      "title": "PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04554680",
      "title": "Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy",
      "status": "UNKNOWN",
      "last_update": "2021-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04619316",
      "title": "Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition",
      "status": "UNKNOWN",
      "last_update": "2023-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04675710",
      "title": "Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04739566",
      "title": "Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer",
      "status": "WITHDRAWN",
      "last_update": "2024-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04940052",
      "title": "Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05102292",
      "title": "The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation",
      "status": "UNKNOWN",
      "last_update": "2023-08-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05182931",
      "title": "A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)",
      "status": "UNKNOWN",
      "last_update": "2023-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06362694",
      "title": "Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy",
      "status": "UNKNOWN",
      "last_update": "2024-04-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07010393",
      "title": "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "BRAF V600E",
     "dabrafenib",
     "vemurafenib"
    ]
   },
   "NTRK": {
    "n": 10,
    "n_observational": 1,
    "n_active": 8,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03093116",
      "title": "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",
      "status": "RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05783323",
      "title": "Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06195228",
      "title": "A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06482086",
      "title": "Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2024-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02568267",
      "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02576431",
      "title": "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02650401",
      "title": "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644315",
      "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07010393",
      "title": "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "NTRK",
     "larotrectinib",
     "entrectinib"
    ]
   },
   "VEGFR": {
    "n": 58,
    "n_observational": 9,
    "n_active": 16,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT06195228",
      "title": "A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06374602",
      "title": "Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06482086",
      "title": "Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2024-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06860971",
      "title": "A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07092514",
      "title": "Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00095693",
      "title": "Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2014-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00126568",
      "title": "Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2018-01-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00389441",
      "title": "Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2013-11-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00390325",
      "title": "Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2024-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00654238",
      "title": "Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2019-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00655655",
      "title": "Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00784303",
      "title": "Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology",
      "status": "COMPLETED",
      "last_update": "2020-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00887107",
      "title": "Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma",
      "status": "COMPLETED",
      "last_update": "2009-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00984282",
      "title": "Nexavar\u00ae Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-09-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01025453",
      "title": "Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01141309",
      "title": "Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01263951",
      "title": "Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone",
      "status": "UNKNOWN",
      "last_update": "2021-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01286753",
      "title": "A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation",
      "status": "COMPLETED",
      "last_update": "2016-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01321554",
      "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)",
      "status": "COMPLETED",
      "last_update": "2023-06-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01438554",
      "title": "Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",
      "status": "COMPLETED",
      "last_update": "2018-08-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01496313",
      "title": "To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2025-10-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01502410",
      "title": "Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01728623",
      "title": "A Study of E7080 in Subjects With Advanced Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2020-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01736878",
      "title": "Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2013-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01811212",
      "title": "Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02084732",
      "title": "Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study",
      "status": "COMPLETED",
      "last_update": "2019-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02114658",
      "title": "Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2017-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02143726",
      "title": "Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02432274",
      "title": "Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma",
      "status": "COMPLETED",
      "last_update": "2023-07-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02592356",
      "title": "Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer",
      "status": "COMPLETED",
      "last_update": "2024-03-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02657369",
      "title": "A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)",
      "status": "TERMINATED",
      "last_update": "2019-10-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02702388",
      "title": "A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",
      "status": "COMPLETED",
      "last_update": "2021-11-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02726503",
      "title": "Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2020-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02915172",
      "title": "Lenvatinib and Capecitabine in Patients With Advanced Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2017-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02966093",
      "title": "A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China",
      "status": "COMPLETED",
      "last_update": "2022-01-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02973997",
      "title": "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)",
      "status": "COMPLETED",
      "last_update": "2025-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03139747",
      "title": "UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone",
      "status": "SUSPENDED",
      "last_update": "2021-10-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03506048",
      "title": "Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2022-11-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03565536",
      "title": "Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03573960",
      "title": "A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2026-03-06",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03630120",
      "title": "Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2021-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03690388",
      "title": "A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03732495",
      "title": "Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas",
      "status": "UNKNOWN",
      "last_update": "2022-03-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03914300",
      "title": "Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04171622",
      "title": "Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04321954",
      "title": "Lenvatinib in Locally Advanced Invasive Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04731740",
      "title": "Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer",
      "status": "WITHDRAWN",
      "last_update": "2024-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04858867",
      "title": "Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)",
      "status": "UNKNOWN",
      "last_update": "2023-10-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05660954",
      "title": "Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.",
      "status": "COMPLETED",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05696548",
      "title": "Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05949424",
      "title": "OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults",
      "status": "UNKNOWN",
      "last_update": "2023-11-29",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06062563",
      "title": "Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-10-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06321120",
      "title": "Using Chronobiology to Improve Lenvatinib Efficacy",
      "status": "UNKNOWN",
      "last_update": "2024-03-20",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06848920",
      "title": "Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07010393",
      "title": "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07252661",
      "title": "Study of ACC-1898 in Adult Participants With Advanced Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "VEGFR",
     "lenvatinib",
     "sorafenib"
    ]
   },
   "PD-1": {
    "n": 36,
    "n_observational": 3,
    "n_active": 19,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05852223",
      "title": "Pembrolizumab in High-risk Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06195228",
      "title": "A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06374602",
      "title": "Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06638931",
      "title": "Agnostic Therapy in Rare Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06787911",
      "title": "Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-01-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06970353",
      "title": "Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02404441",
      "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02628067",
      "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02688608",
      "title": "Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2022-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02973997",
      "title": "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)",
      "status": "COMPLETED",
      "last_update": "2025-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03012620",
      "title": "Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types",
      "status": "COMPLETED",
      "last_update": "2024-02-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03072160",
      "title": "Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03211117",
      "title": "Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2020-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03360890",
      "title": "Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03435952",
      "title": "Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04171622",
      "title": "Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04234113",
      "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04238624",
      "title": "Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04418167",
      "title": "JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations",
      "status": "SUSPENDED",
      "last_update": "2025-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04521348",
      "title": "Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2025-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04524884",
      "title": "Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study",
      "status": "UNKNOWN",
      "last_update": "2020-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04579757",
      "title": "Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04612894",
      "title": "Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer",
      "status": "UNKNOWN",
      "last_update": "2020-11-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04675710",
      "title": "Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04731740",
      "title": "Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer",
      "status": "WITHDRAWN",
      "last_update": "2024-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802876",
      "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05059470",
      "title": "IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC",
      "status": "TERMINATED",
      "last_update": "2026-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05119296",
      "title": "Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05453799",
      "title": "Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer",
      "status": "SUSPENDED",
      "last_update": "2026-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05659186",
      "title": "PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-12-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05708950",
      "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)",
      "status": "COMPLETED",
      "last_update": "2026-06-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06856278",
      "title": "Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-03-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07010393",
      "title": "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "PD-1",
     "pembrolizumab"
    ]
   },
   "TSHR": {
    "n": 33,
    "n_observational": 8,
    "n_active": 9,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03841617",
      "title": "The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05668962",
      "title": "Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC",
      "status": "RECRUITING",
      "last_update": "2024-12-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06405217",
      "title": "Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment",
      "status": "RECRUITING",
      "last_update": "2024-05-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06431620",
      "title": "Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2024-05-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06440850",
      "title": "Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00001730",
      "title": "Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.",
      "status": "COMPLETED",
      "last_update": "2008-03-04",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054756",
      "title": "Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities",
      "status": "COMPLETED",
      "last_update": "2018-08-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00085293",
      "title": "Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131",
      "status": "COMPLETED",
      "last_update": "2018-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00181168",
      "title": "Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00196729",
      "title": "Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration",
      "status": "COMPLETED",
      "last_update": "2015-03-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00295763",
      "title": "A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.",
      "status": "COMPLETED",
      "last_update": "2015-03-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00415233",
      "title": "High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00435851",
      "title": "Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients",
      "status": "UNKNOWN",
      "last_update": "2007-02-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00525135",
      "title": "Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2015-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00604318",
      "title": "Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-10",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00970359",
      "title": "Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244",
      "status": "COMPLETED",
      "last_update": "2017-04-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01341886",
      "title": "Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2011-04-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01837745",
      "title": "Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-05-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02145143",
      "title": "Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study",
      "status": "COMPLETED",
      "last_update": "2025-06-18",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02278198",
      "title": "Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123",
      "status": "COMPLETED",
      "last_update": "2019-10-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02304757",
      "title": "99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis",
      "status": "COMPLETED",
      "last_update": "2021-11-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03244956",
      "title": "Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2026-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03276988",
      "title": "Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients",
      "status": "COMPLETED",
      "last_update": "2020-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04137185",
      "title": "Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients",
      "status": "COMPLETED",
      "last_update": "2024-03-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04447183",
      "title": "rhTSH for Radioactive Iodine Remnant Ablation in Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04868045",
      "title": "Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer",
      "status": "WITHDRAWN",
      "last_update": "2023-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04880798",
      "title": "Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-05-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04964284",
      "title": "rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)",
      "status": "COMPLETED",
      "last_update": "2026-09-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04971473",
      "title": "Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal",
      "status": "COMPLETED",
      "last_update": "2024-03-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06235814",
      "title": "Molecular Analysis for Precision Surgery in Thyroid Cancer Trial",
      "status": "COMPLETED",
      "last_update": "2026-02-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06422702",
      "title": "The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06790589",
      "title": "COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07239674",
      "title": "Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "TSH receptor",
     "TSHR",
     "thyrotropin"
    ]
   }
  },
  "by_drug": {
   "ALECTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03131206",
      "title": "A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2021-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644315",
      "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BUPARLISIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01830504",
      "title": "A Multicenter Phase II Pilot Open Label",
      "status": "UNKNOWN",
      "last_update": "2016-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CERITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT02289144",
      "title": "Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer",
      "status": "WITHDRAWN",
      "last_update": "2019-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "COPANLISIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04462471",
      "title": "Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers",
      "status": "COMPLETED",
      "last_update": "2025-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CRIZOTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02568267",
      "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DABRAFENIB": {
    "n": 24,
    "n_observational": 2,
    "n_active": 14,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03975231",
      "title": "Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06079333",
      "title": "NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)",
      "status": "RECRUITING",
      "last_update": "2023-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06195228",
      "title": "A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06475989",
      "title": "Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06482086",
      "title": "Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2024-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07440290",
      "title": "DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01534897",
      "title": "Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436",
      "status": "COMPLETED",
      "last_update": "2017-03-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01723202",
      "title": "Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2025-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01947023",
      "title": "Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02034110",
      "title": "Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers",
      "status": "COMPLETED",
      "last_update": "2023-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03244956",
      "title": "Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2026-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04238624",
      "title": "Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04418167",
      "title": "JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations",
      "status": "SUSPENDED",
      "last_update": "2025-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04439292",
      "title": "Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04544111",
      "title": "PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04554680",
      "title": "Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy",
      "status": "UNKNOWN",
      "last_update": "2021-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04619316",
      "title": "Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition",
      "status": "UNKNOWN",
      "last_update": "2023-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04675710",
      "title": "Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04739566",
      "title": "Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer",
      "status": "WITHDRAWN",
      "last_update": "2024-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04940052",
      "title": "Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05182931",
      "title": "A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)",
      "status": "UNKNOWN",
      "last_update": "2023-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06362694",
      "title": "Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy",
      "status": "UNKNOWN",
      "last_update": "2024-04-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07010393",
      "title": "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ENCORAFENIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04061980",
      "title": "Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ENTRECTINIB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06195228",
      "title": "A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06482086",
      "title": "Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2024-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02568267",
      "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02650401",
      "title": "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644315",
      "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IMETELSTAT": {
    "n": 1,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00121628",
      "title": "A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2013-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LAROTRECTINIB": {
    "n": 6,
    "n_observational": 0,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05783323",
      "title": "Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06195228",
      "title": "A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06482086",
      "title": "Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2024-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02576431",
      "title": "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07010393",
      "title": "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MOTESANIB": {
    "n": 1,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00121628",
      "title": "A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2013-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAPORAFENIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05907304",
      "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OMIPALISIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02152995",
      "title": "Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PLIXORAFENIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05503797",
      "title": "A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations",
      "status": "RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PRALSETINIB": {
    "n": 6,
    "n_observational": 3,
    "n_active": 4,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06195228",
      "title": "A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06482086",
      "title": "Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2024-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07704658",
      "title": "Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03037385",
      "title": "Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-05-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04760288",
      "title": "A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).",
      "status": "WITHDRAWN",
      "last_update": "2024-01-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07010393",
      "title": "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REGORAFENIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02657551",
      "title": "A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03475953",
      "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-03-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REPOTRECTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03093116",
      "title": "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",
      "status": "RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SELPERCATINIB": {
    "n": 9,
    "n_observational": 3,
    "n_active": 9,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05668962",
      "title": "Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC",
      "status": "RECRUITING",
      "last_update": "2024-12-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06195228",
      "title": "A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06458036",
      "title": "Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03157128",
      "title": "A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03899792",
      "title": "A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04211337",
      "title": "A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04280081",
      "title": "A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04759911",
      "title": "Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07010393",
      "title": "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SORAFENIB": {
    "n": 17,
    "n_observational": 3,
    "n_active": 3,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06482086",
      "title": "Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2024-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00095693",
      "title": "Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2014-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00126568",
      "title": "Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2018-01-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00390325",
      "title": "Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2024-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00654238",
      "title": "Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2019-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00887107",
      "title": "Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma",
      "status": "COMPLETED",
      "last_update": "2009-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00984282",
      "title": "Nexavar\u00ae Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-09-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01025453",
      "title": "Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01141309",
      "title": "Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01263951",
      "title": "Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone",
      "status": "UNKNOWN",
      "last_update": "2021-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01502410",
      "title": "Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01736878",
      "title": "Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2013-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02084732",
      "title": "Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study",
      "status": "COMPLETED",
      "last_update": "2019-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02114658",
      "title": "Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2017-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02143726",
      "title": "Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03565536",
      "title": "Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03630120",
      "title": "Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2021-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SUNITINIB": {
    "n": 8,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00381641",
      "title": "Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2025-03-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00428220",
      "title": "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.",
      "status": "COMPLETED",
      "last_update": "2019-06-27",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00510640",
      "title": "Thyroid Cancer and Sunitinib",
      "status": "COMPLETED",
      "last_update": "2026-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00519896",
      "title": "Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2017-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00668811",
      "title": "Sutent Adjunctive Treatment of Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2020-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05660954",
      "title": "Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.",
      "status": "COMPLETED",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05949424",
      "title": "OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults",
      "status": "UNKNOWN",
      "last_update": "2023-11-29",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SUNITINIB MALATE": {
    "n": 8,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00381641",
      "title": "Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2025-03-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00428220",
      "title": "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.",
      "status": "COMPLETED",
      "last_update": "2019-06-27",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00510640",
      "title": "Thyroid Cancer and Sunitinib",
      "status": "COMPLETED",
      "last_update": "2026-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00519896",
      "title": "Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2017-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00668811",
      "title": "Sutent Adjunctive Treatment of Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2020-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05660954",
      "title": "Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.",
      "status": "COMPLETED",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05949424",
      "title": "OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults",
      "status": "UNKNOWN",
      "last_update": "2023-11-29",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TASELISIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "THYROTROPIN": {
    "n": 32,
    "n_observational": 8,
    "n_active": 8,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03841617",
      "title": "The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05668962",
      "title": "Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC",
      "status": "RECRUITING",
      "last_update": "2024-12-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06405217",
      "title": "Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment",
      "status": "RECRUITING",
      "last_update": "2024-05-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06431620",
      "title": "Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2024-05-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06440850",
      "title": "Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00001730",
      "title": "Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.",
      "status": "COMPLETED",
      "last_update": "2008-03-04",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054756",
      "title": "Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities",
      "status": "COMPLETED",
      "last_update": "2018-08-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00085293",
      "title": "Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131",
      "status": "COMPLETED",
      "last_update": "2018-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00181168",
      "title": "Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00196729",
      "title": "Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration",
      "status": "COMPLETED",
      "last_update": "2015-03-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00295763",
      "title": "A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.",
      "status": "COMPLETED",
      "last_update": "2015-03-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00415233",
      "title": "High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00435851",
      "title": "Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients",
      "status": "UNKNOWN",
      "last_update": "2007-02-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00525135",
      "title": "Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2015-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00604318",
      "title": "Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-10",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00970359",
      "title": "Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244",
      "status": "COMPLETED",
      "last_update": "2017-04-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01341886",
      "title": "Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2011-04-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01837745",
      "title": "Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-05-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02145143",
      "title": "Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study",
      "status": "COMPLETED",
      "last_update": "2025-06-18",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02278198",
      "title": "Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123",
      "status": "COMPLETED",
      "last_update": "2019-10-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02304757",
      "title": "99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis",
      "status": "COMPLETED",
      "last_update": "2021-11-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03244956",
      "title": "Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2026-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03276988",
      "title": "Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients",
      "status": "COMPLETED",
      "last_update": "2020-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04137185",
      "title": "Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients",
      "status": "COMPLETED",
      "last_update": "2024-03-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04447183",
      "title": "rhTSH for Radioactive Iodine Remnant Ablation in Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04868045",
      "title": "Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer",
      "status": "WITHDRAWN",
      "last_update": "2023-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04880798",
      "title": "Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-05-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04964284",
      "title": "rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)",
      "status": "COMPLETED",
      "last_update": "2026-09-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04971473",
      "title": "Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal",
      "status": "COMPLETED",
      "last_update": "2024-03-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06235814",
      "title": "Molecular Analysis for Precision Surgery in Thyroid Cancer Trial",
      "status": "COMPLETED",
      "last_update": "2026-02-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06422702",
      "title": "The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06790589",
      "title": "COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "THYROTROPIN ALFA": {
    "n": 30,
    "n_observational": 5,
    "n_active": 7,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03841617",
      "title": "The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05668962",
      "title": "Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC",
      "status": "RECRUITING",
      "last_update": "2024-12-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06405217",
      "title": "Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment",
      "status": "RECRUITING",
      "last_update": "2024-05-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06431620",
      "title": "Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2024-05-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06440850",
      "title": "Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00001730",
      "title": "Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.",
      "status": "COMPLETED",
      "last_update": "2008-03-04",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00085293",
      "title": "Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131",
      "status": "COMPLETED",
      "last_update": "2018-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00181168",
      "title": "Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00196729",
      "title": "Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration",
      "status": "COMPLETED",
      "last_update": "2015-03-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00295763",
      "title": "A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.",
      "status": "COMPLETED",
      "last_update": "2015-03-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00415233",
      "title": "High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00435851",
      "title": "Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients",
      "status": "UNKNOWN",
      "last_update": "2007-02-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00525135",
      "title": "Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2015-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00604318",
      "title": "Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-10",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00926978",
      "title": "Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)",
      "status": "TERMINATED",
      "last_update": "2018-11-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00970359",
      "title": "Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244",
      "status": "COMPLETED",
      "last_update": "2017-04-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01182285",
      "title": "A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin",
      "status": "COMPLETED",
      "last_update": "2018-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01837745",
      "title": "Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-05-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01843062",
      "title": "Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2019-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02145143",
      "title": "Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study",
      "status": "COMPLETED",
      "last_update": "2025-06-18",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02278198",
      "title": "Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123",
      "status": "COMPLETED",
      "last_update": "2019-10-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03215095",
      "title": "RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03244956",
      "title": "Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2026-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03276988",
      "title": "Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients",
      "status": "COMPLETED",
      "last_update": "2020-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04137185",
      "title": "Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients",
      "status": "COMPLETED",
      "last_update": "2024-03-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04447183",
      "title": "rhTSH for Radioactive Iodine Remnant Ablation in Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04554680",
      "title": "Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy",
      "status": "UNKNOWN",
      "last_update": "2021-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04858867",
      "title": "Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)",
      "status": "UNKNOWN",
      "last_update": "2023-10-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04964284",
      "title": "rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)",
      "status": "COMPLETED",
      "last_update": "2026-09-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04971473",
      "title": "Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal",
      "status": "COMPLETED",
      "last_update": "2024-03-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TOVORAFENIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04985604",
      "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VANDETANIB": {
    "n": 16,
    "n_observational": 4,
    "n_active": 2,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT06482086",
      "title": "Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer",
      "status": "RECRUITING",
      "last_update": "2024-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00098345",
      "title": "Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00358956",
      "title": "A Study To Assess ZD6474 (ZACTIMA\u2122) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2017-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00410761",
      "title": "An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2025-09-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00514046",
      "title": "Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2020-12-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00537095",
      "title": "Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00923247",
      "title": "A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)",
      "status": "TERMINATED",
      "last_update": "2018-11-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00937417",
      "title": "S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2017-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01298323",
      "title": "Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment",
      "status": "COMPLETED",
      "last_update": "2026-04-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01496313",
      "title": "To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2025-10-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01539655",
      "title": "Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib",
      "status": "COMPLETED",
      "last_update": "2017-05-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01661179",
      "title": "Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-12-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01876784",
      "title": "Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2024-07-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03630120",
      "title": "Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer",
      "status": "TERMINATED",
      "last_update": "2021-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04211337",
      "title": "A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04760288",
      "title": "A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).",
      "status": "WITHDRAWN",
      "last_update": "2024-01-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VEMURAFENIB": {
    "n": 9,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05768178",
      "title": "DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.",
      "status": "RECRUITING",
      "last_update": "2025-11-24",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06440850",
      "title": "Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01286753",
      "title": "A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation",
      "status": "COMPLETED",
      "last_update": "2016-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01709292",
      "title": "Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02145143",
      "title": "Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study",
      "status": "COMPLETED",
      "last_update": "2025-06-18",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02456701",
      "title": "Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379",
      "status": "COMPLETED",
      "last_update": "2017-09-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03176485",
      "title": "Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors",
      "status": "COMPLETED",
      "last_update": "2019-01-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03181100",
      "title": "Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04462471",
      "title": "Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers",
      "status": "COMPLETED",
      "last_update": "2025-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "XL-281": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00451880",
      "title": "Study of XL281 in Adults With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2011-10-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}